Produktdetaljer
Biographical note
Tony Kenedy is Vice President of Development at Trigen, Ltd in London, U.K. Dr. Kennedy, a Medical Research Council Postdoctoral Research Fellow at The School of Pharmacy, London University, U.K., was awarded his Ph.D. by London University, U.K. and was previously the Global Head of Project Management at Roche, Switzerland. He was the editor of the first edition of Pharmaceutical Project Management which was published by Marcel Dekker in 1998, and his career has been devoted to the discovery and development of novel drugs while working in large pharmaceutical and small biotech companies. Dr. Kennedy has directed global drug development teams in several therapeutic areas including cardiovascular, gastrointestinal, infectious disease, rheumatology and oncology, and led the Roche-Gilead joint development team that took the flu antiviral Tamiflu to registration three years after the discovery of the molecule.
Produktdetaljer
Biographical note
Tony Kenedy is Vice President of Development at Trigen, Ltd in London, U.K. Dr. Kennedy, a Medical Research Council Postdoctoral Research Fellow at The School of Pharmacy, London University, U.K., was awarded his Ph.D. by London University, U.K. and was previously the Global Head of Project Management at Roche, Switzerland. He was the editor of the first edition of Pharmaceutical Project Management which was published by Marcel Dekker in 1998, and his career has been devoted to the discovery and development of novel drugs while working in large pharmaceutical and small biotech companies. Dr. Kennedy has directed global drug development teams in several therapeutic areas including cardiovascular, gastrointestinal, infectious disease, rheumatology and oncology, and led the Roche-Gilead joint development team that took the flu antiviral Tamiflu to registration three years after the discovery of the molecule.